tetano
Editor, Senior Moderator
Adv Ther
. 2023 Jul 1.
doi: 10.1007/s12325-023-02580-4. Online ahead of print. Factors That Predict a Sustained Humoral Response to COVID-19 Vaccines in Kidney Transplant Recipients
Pierre Pommerolle[SUP] 1 [/SUP], Pierre Laurent[SUP] 2 [/SUP], Claire Presne[SUP] 2 [/SUP], François Brazier[SUP] 2 [/SUP], Maïté Jaureguy[SUP] 2 [/SUP], Coralie Poulain[SUP] 2 [/SUP], Gauthier Flahaut[SUP] 2 [/SUP], Hakim Mazouz[SUP] 2 [/SUP], Etienne Brochot[SUP] 3 [/SUP], Gabriel Choukroun[SUP] 2 [/SUP], Ophélie Fourdinier[SUP] 2 [/SUP]
Affiliations
Introduction: Kidney transplant recipients (KTRs) produce a weak humoral response to coronavirus disease 2019 (COVID-19) vaccines. However, the factors associated with the quality of the serological response to three doses of COVID-19 vaccine have not been unambiguously identified.
Methods: We included KTRs followed in the Nephrology Department at Amiens University Hospital (Amiens, France) between June and December 2021 who had received three doses of a COVID-19 mRNA vaccine (or two doses plus an episode of polymerase chain reaction-confirmed COVID-19). The lack of a humoral response was defined as an antibody titer below 7.1 binding antibody units (BAU)/mL, and an optimal response was defined as an antibody titer above 264 BAU/mL.
Results: Of the 371 patients included, 246 (66.3%) were seropositive, and 97 (26.1%) had an optimal response. In a multivariate analysis, the only factor associated with seropositivity was a history of COVID-19 [odds ratio (OR) 87.2; 95% confidence interval (CI) (7.88-965.0); p < 0.0001], while the main factors associated with non-response were female sex [OR 0.28; 95%CI (0.15-0.51); p < 0.0001], less than 36 months between kidney transplantation and vaccination [OR 0.26; 95%CI (0.13-0.52); p < 0.0001], a higher creatinine level [OR 0.33; 95%CI (0.19-0.56); p < 0.0001], the use of tacrolimus [OR 0.23; 95%CI (0.12-0.45); p < 0.0001], the use of belatacept [OR 0.01; 95%CI (0.001-0.20); p = 0.002] and three-drug immunosuppression [OR 0.39; 95%CI (0.19-0.78); p = 0.015]. A history of COVID-19 was associated with an optimal response [OR 4.03; 95%CI (2.09-7.79); p < 0.0001], while an older age at vaccination [OR 0.97; 95%CI (0.95-0.99); p = 0.002], less than 36 months between kidney transplantation and vaccination [OR 0.35; 95%CI (0.18-0.69); p = 0.002], a higher creatinine level [OR 0.60; 95%CI (0.38-0.93); p = 0.02], three-drug immunosuppression [OR 0.45; 95%CI (0.27-0.76); p = 0.003] were associated with a poorer response.
Conclusion: We identified factors associated with a humoral response to a COVID-19 mRNA vaccine in KTRs. These findings might help physicians to optimize vaccination in KTRs.
Keywords: COVID-19; Humoral response; Kidney transplantation; SARS-CoV-2; mRNA vaccine.
. 2023 Jul 1.
doi: 10.1007/s12325-023-02580-4. Online ahead of print. Factors That Predict a Sustained Humoral Response to COVID-19 Vaccines in Kidney Transplant Recipients
Pierre Pommerolle[SUP] 1 [/SUP], Pierre Laurent[SUP] 2 [/SUP], Claire Presne[SUP] 2 [/SUP], François Brazier[SUP] 2 [/SUP], Maïté Jaureguy[SUP] 2 [/SUP], Coralie Poulain[SUP] 2 [/SUP], Gauthier Flahaut[SUP] 2 [/SUP], Hakim Mazouz[SUP] 2 [/SUP], Etienne Brochot[SUP] 3 [/SUP], Gabriel Choukroun[SUP] 2 [/SUP], Ophélie Fourdinier[SUP] 2 [/SUP]
Affiliations
- PMID: 37392339
- DOI: 10.1007/s12325-023-02580-4
Introduction: Kidney transplant recipients (KTRs) produce a weak humoral response to coronavirus disease 2019 (COVID-19) vaccines. However, the factors associated with the quality of the serological response to three doses of COVID-19 vaccine have not been unambiguously identified.
Methods: We included KTRs followed in the Nephrology Department at Amiens University Hospital (Amiens, France) between June and December 2021 who had received three doses of a COVID-19 mRNA vaccine (or two doses plus an episode of polymerase chain reaction-confirmed COVID-19). The lack of a humoral response was defined as an antibody titer below 7.1 binding antibody units (BAU)/mL, and an optimal response was defined as an antibody titer above 264 BAU/mL.
Results: Of the 371 patients included, 246 (66.3%) were seropositive, and 97 (26.1%) had an optimal response. In a multivariate analysis, the only factor associated with seropositivity was a history of COVID-19 [odds ratio (OR) 87.2; 95% confidence interval (CI) (7.88-965.0); p < 0.0001], while the main factors associated with non-response were female sex [OR 0.28; 95%CI (0.15-0.51); p < 0.0001], less than 36 months between kidney transplantation and vaccination [OR 0.26; 95%CI (0.13-0.52); p < 0.0001], a higher creatinine level [OR 0.33; 95%CI (0.19-0.56); p < 0.0001], the use of tacrolimus [OR 0.23; 95%CI (0.12-0.45); p < 0.0001], the use of belatacept [OR 0.01; 95%CI (0.001-0.20); p = 0.002] and three-drug immunosuppression [OR 0.39; 95%CI (0.19-0.78); p = 0.015]. A history of COVID-19 was associated with an optimal response [OR 4.03; 95%CI (2.09-7.79); p < 0.0001], while an older age at vaccination [OR 0.97; 95%CI (0.95-0.99); p = 0.002], less than 36 months between kidney transplantation and vaccination [OR 0.35; 95%CI (0.18-0.69); p = 0.002], a higher creatinine level [OR 0.60; 95%CI (0.38-0.93); p = 0.02], three-drug immunosuppression [OR 0.45; 95%CI (0.27-0.76); p = 0.003] were associated with a poorer response.
Conclusion: We identified factors associated with a humoral response to a COVID-19 mRNA vaccine in KTRs. These findings might help physicians to optimize vaccination in KTRs.
Keywords: COVID-19; Humoral response; Kidney transplantation; SARS-CoV-2; mRNA vaccine.